ClinicalTrials.gg
CompletedNCT06799884Updated Mar 11, 2025

A Drug-drug Interaction Trial in Healthy Female Participants to Investigate the Effect of Aprocitentan on Combined Hormonal Contraceptives

A Phase 1 interventional study of Ethinyl Estradiol / Levonorgestrel Oral Tablet and Aprocitentan in Drug Drug Interaction, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 1 site in Czechia. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-11.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

The goal of this clinical trial is to learn if drug aprocitentan has an effect on hormonal contraceptives in healthy female volunteers. The main question it aims to answer is:

Does aprocitentan modify the fate of hormonal contraceptives in the body?

Trial participants will:

  • Take a single dose of hormonal contraceptives (fixed combination) alone
  • Take aprocitentan every day for 2 weeks
  • Take a single dose of the same hormonal contraceptives at the same time as the 10th administration of aprocitentan.
Read the detailed description

The main objective of the trial is to evaluate the influence of aprocitentan at steady-state on the single-dose pharmacokinetics (PK) of combined oral contraceptives.

19 healthy female participants will be enrolled to have at least 16 evaluable participants.

Following a screening period (from full signature of the informed consent form [ICF] to enrollment; 10 to 28 days prior to first trial intervention administration), eligible participants (meeting all inclusion criteria and none of the exclusion criteria) will be enrolled in the trial to participate in two sequential trial periods, Trial Period A and Trial Period B, with an in-between period of at least 7 days. Trial Period B will be split into two sequential sub-periods, Trial Period B1 and Trial Period B2.

  • Trial Period A: Starts with a single administration of trial intervention on Day 1 and ends with an End-of-Trial Period (EoTP) assessment on Day 5. Trial intervention administration on Day 1 will be followed by a 96-hour observation period for safety monitoring and PK sampling.
  • Trial Period B1: Trial intervention will be administered from Day 1 to Day 9, with assessments for PK sampling and safety monitoring performed throughout.
  • Trial Period B2: Starts with administration of trial intervention on Day 10 and ends with an EoTP assessment on Day 14. Trial intervention will be administered from Day 10 to Day 13, with assessments for PK sampling and safety monitoring performed throughout.

Trial participation of an individual participant ends with the completion of the Participant Last Visit, which will be performed 10-14 days after the last administration of trial intervention. A post-trial safety follow up is performed 30-40 days after last administration of trial intervention.

02

Conditions studied

  • Drug Drug Interaction
03

In context

Lead sponsor

Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.

Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated form (ICF) prior to any trial-mandated procedure.
  • Healthy female participants aged from 18 to 65 years at the time of signing the ICF.
  • Ability to communicate well with the investigator, in a language understandable to the participant, and to understand and comply with the trial requirements.
  • (BMI) of 18.0 to 30.0 kg/m2 (inclusive) at Screening.
  • Normal or not abnormal systolic blood pressure (SBP) 100-139 mmHg, diastolic blood pressure (DBP) 50-90 mmHg, and pulse rate 45-90 bpm (inclusive), measured on either arm, after 5 min in the supine position at Screening and on Day 1 (predose) of Trial Period A (TP A).
  • Participant of who has a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day 1 (predose) of TP A.
  • Participant of childbearing potential who agrees to use two reliable methods of non- hormonal from Screening and for at least 30 days after the last trial intervention administration, or be sexually inactive, or have a vasectomized partner.
  • Participant of non-childbearing potential, i.e., (defined as 12 consecutive months with no menses without an alternative medical cause, confirmed by an follicle stimulating hormone test), with previous bilateral salpingectomy, bilateral salpingo-oophorectomy, or hysterectomy, or with premature ovarian failure (confirmed by a specialist), XY genotype, Turner syndrome, uterine agenesis).

Exclusion criteria

Exclusion Criteria:

  • Known to aprocitentan, ethinylestradiol, or levonorgestrel, or treatments of the same class, or any of their .
  • findings on the physical examination at Screening.
  • Clinically relevant abnormalities on 12-lead (ECG), measured after 5 min in a supine position at Screening or on Day 1 (pre-dose) of TP A.
  • Clinically relevant findings in clinical laboratory tests (hematology and clinical chemistry) at Screening.
  • History of major medical or surgical disorders which, in the opinion of the investigator, are likely to interfere with the absorption, distribution, metabolism, or excretion of the trial interventions (appendectomy and herniotomy allowed if performed > 12 weeks prior to first trial intervention administration, cholecystectomy not allowed).
  • Acute, ongoing, recurrent, or chronic systemic disease able to interfere with the evaluation of the trial results.
  • Previous clinically relevant history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal reactions.
  • Previous therapy with hormonal or hormone replacement therapy within 2 months prior to first trial intervention administration.
  • Pregnant, planning to become pregnant during the trial, or lactating participant of .
  • Participant presenting any for LOETTE®
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Ethinyl estradiol/levonorgestrel (LOETTE)

    In Trial Period A, participants will receive a single oral dose of 20µg ethinyl estradiol/100 µg levonorgestrel in the morning of Day 1.

    Drug: Ethinyl Estradiol / Levonorgestrel Oral Tablet

  • Experimental
    Aprocitentan

    In Trial Period B1, participants will receive a once daily oral dose of 25 mg aprocitentan in the morning of Day 1 to Day 9.

    Drug: Aprocitentan

  • Experimental
    Aprocitentan and ethinyl estradiol/levonorgestrel (LOETTE)

    In Trial Period B2, participants will receive a once daily oral dose of 25 mg aprocitentan in the morning of Day 10 to Day 13. On Day 10, participants will receive a single oral dose of 20µg ethinyl estradiol/100 µg levonorgestrel, administered concomitantly to aprocitentan.

    Drug: Ethinyl Estradiol / Levonorgestrel Oral Tablet · Drug: Aprocitentan

Interventions

  • DrugEthinyl Estradiol / Levonorgestrel Oral Tablet

    Drug pages: Ethinyl Estradiol · Levonorgestrel

    Coated tablet of 20 µg ethinyl estradiol and 100 µg levonorgestrel

    Also known as: LOETTE

  • Film-coated tablet of aprocitentan 25 mg

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration (Cmax) of ethinyl estradiol/levonorgestrel

    The measured individual plasma concentrations will be used to directly obtain Cmax.

    Time frame: TP A: On Day 1 (pre-dose) and predefined times up to 96 hours post-dose (Day 5); TP B2: On Day 10 (pre-dose) and predefined times up to 96 hours post-dose (Day 14)

  2. Time to maximum plasma concentration (tmax) of ethinyl estradiol/levonorgestrel

    The measured individual plasma concentrations will be used to directly obtain tmax.

    Time frame: TP A: On Day 1 (pre-dose) and predefined times up to 96 hours post-dose (Day 5); TP B2: On Day 10 (pre-dose) and predefined times up to 96 hours post-dose (Day 14)

  3. Area under the Plasma Concentration-Time Curve (AUC 0-t) of ethinyl estradiol/levonorgestrel

    Change to AUC 0-t will be derived by non compartmental analysis of the concentration-time profiles.

    Time frame: TP A: On Day 1 (pre-dose) and predefined times up to 96 hours post-dose (Day 5); TP B2: On Day 10 (pre-dose) and predefined times up to 96 hours post-dose (Day 14)

  4. Area under the Plasma Concentration-Time Curve (AUC 0-infinity) of ethinyl estradiol/levonorgestrel

    Change to AUC 0-infinity will be derived by non compartmental analysis of the concentration-time profiles.

    Time frame: TP A: On Day 1 (pre-dose) and predefined times up to 96 hours post-dose (Day 5); TP B2: On Day 10 (pre-dose) and predefined times up to 96 hours post-dose (Day 14)

  5. Terminal half-life (t1/2) of ethinyl estradiol/levonorgestrel

    t1/2 will be derived by non compartmental analysis of the concentration-time profiles.

    Time frame: TP A: On Day 1 (pre-dose) and predefined times up to 96 hours post-dose (Day 5); TP B2: On Day 10 (pre-dose) and predefined times up to 96 hours post-dose (Day 14)

  6. Trough plasma concentration (Ctrough) of aprocitentan

    Ctrough will be based on measured individual plasma concentrations of aprocitentan.

    Time frame: Prior to administration on Day 10, 11, 12 and 13 in TP B2

07

Study locations

1 site
  • CEPHA s.r.o.
    Pilsen, 323 00, Czechia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2025 to primary completion in Feb 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2025
First posted
Jan 29, 2025
StartActual
Jan 18, 2025
Primary completionActual
Feb 21, 2025
CompletionActual
Feb 21, 2025
Last update
Mar 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06799884
Responsible party
Sponsor
First posted
Jan 29, 2025
Start date
Jan 18, 2025
Primary completion
Feb 21, 2025
Completion
Feb 21, 2025
Last update
Mar 11, 2025

Study contacts

Clinical Trials
study director · Idorsia Pharmaceuticals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ethinyl Estradiol · Levonorgestrel · Aprocitentan

Start the discussion